[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @onco_park Byung-June Park Byung-June Park posts on X about $4528t, ono, rates the most. They currently have XXXXX followers and XX posts still getting attention that total X engagements in the last XX hours. ### Engagements: undefined [#](/creator/twitter::1211752034942078977/interactions)  - X Week XX -XX% - X Month XXXXX +244% - X Months XXXXX -XX% - X Year XXXXXXX +62% ### Mentions: undefined [#](/creator/twitter::1211752034942078977/posts_active)  - X Week X -XX% - X Month XX -XXXX% - X Months XX -XX% - X Year XXX +24% ### Followers: XXXXX [#](/creator/twitter::1211752034942078977/followers)  - X Week XXXXX +0.04% - X Month XXXXX +0.21% - X Months XXXXX +3.10% - X Year XXXXX +42% ### CreatorRank: undefined [#](/creator/twitter::1211752034942078977/influencer_rank)  ### Social Influence [#](/creator/twitter::1211752034942078977/influence) --- **Social topic influence** [$4528t](/topic/$4528t) 2.44%, [ono](/topic/ono) 2.44%, [rates](/topic/rates) XXXX% **Top accounts mentioned or mentioned by** [@bymadeleinea](/creator/undefined) [@halozymeinc](/creator/undefined) [@incyte](/creator/undefined) [@halozymeincs](/creator/undefined) [@pdrennert](/creator/undefined) [@dewdiligence](/creator/undefined) [@jacobplieth](/creator/undefined) [@franksdavid](/creator/undefined) [@jivetur88775834](/creator/undefined) [@jacksha90859576](/creator/undefined) [@follow_5](/creator/undefined) ### Top Social Posts [#](/creator/twitter::1211752034942078977/posts) --- Top posts by engagements in the last XX hours "Q224_Genmab's Oncology X. Genmab's R&D strategy will focus on advancing mid-to-late-stage projects like EPKINLY Tivdak acasunlimab and Rina-S. While early-stage investments have reached a satisfactory level future efforts will be more moderate prioritizing pivotal trials and potential registrations for key assets. X. At #ESMO24 updated data on Rina-S will be presented showing significant activity across various FR expression levels compared to Elehere. Genmab plans to initiate a Phase X trial for 2L PROC by the end of 2024. The company attributes Rina-S's superior safety profile to its" [X Link](https://x.com/onco_park/status/1821951433668735007) [@onco_park](/creator/x/onco_park) 2024-08-09T16:47Z 2361 followers, 1960 engagements "Ono Pharmaceutical has inked two key deals with LigaChem Biosciences. First Ono secured worldwide exclusive rights to LCB97 LCB's L1CAM-targeting ADC for solid tumors. Second the companies agreed to collaborate on developing new ADC candidates using LCB's ConjuAll ADC platform" [X Link](https://x.com/onco_park/status/1844304885627453842) [@onco_park](/creator/x/onco_park) 2024-10-10T09:12Z 2361 followers, XXX engagements "J&J has decided not to exercise its license option for HexaBody-CD38. Genmab will discontinue further clinical development of HexaBody-CD38 maintaining its previously stated focus on advancing late-stage assets Rina-S and acasunlimab. HexaBody-CD38 showed slightly higher ORR VGPR and CR rates compared to daratumumab though the differences were not substantial" [X Link](https://x.com/onco_park/status/1899107328022188100) [@onco_park](/creator/x/onco_park) 2025-03-10T14:37Z 2361 followers, 4105 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@onco_park Byung-June Park
Byung-June Park posts on X about $4528t, ono, rates the most. They currently have XXXXX followers and XX posts still getting attention that total X engagements in the last XX hours.
Engagements: undefined #
- X Week XX -XX%
- X Month XXXXX +244%
- X Months XXXXX -XX%
- X Year XXXXXXX +62%
Mentions: undefined #
- X Week X -XX%
- X Month XX -XXXX%
- X Months XX -XX%
- X Year XXX +24%
Followers: XXXXX #
- X Week XXXXX +0.04%
- X Month XXXXX +0.21%
- X Months XXXXX +3.10%
- X Year XXXXX +42%
CreatorRank: undefined #
Social Influence #
Social topic influence $4528t 2.44%, ono 2.44%, rates XXXX%
Top accounts mentioned or mentioned by @bymadeleinea @halozymeinc @incyte @halozymeincs @pdrennert @dewdiligence @jacobplieth @franksdavid @jivetur88775834 @jacksha90859576 @follow_5
Top Social Posts #
Top posts by engagements in the last XX hours
"Q224_Genmab's Oncology X. Genmab's R&D strategy will focus on advancing mid-to-late-stage projects like EPKINLY Tivdak acasunlimab and Rina-S. While early-stage investments have reached a satisfactory level future efforts will be more moderate prioritizing pivotal trials and potential registrations for key assets. X. At #ESMO24 updated data on Rina-S will be presented showing significant activity across various FR expression levels compared to Elehere. Genmab plans to initiate a Phase X trial for 2L PROC by the end of 2024. The company attributes Rina-S's superior safety profile to its"
X Link @onco_park 2024-08-09T16:47Z 2361 followers, 1960 engagements
"Ono Pharmaceutical has inked two key deals with LigaChem Biosciences. First Ono secured worldwide exclusive rights to LCB97 LCB's L1CAM-targeting ADC for solid tumors. Second the companies agreed to collaborate on developing new ADC candidates using LCB's ConjuAll ADC platform"
X Link @onco_park 2024-10-10T09:12Z 2361 followers, XXX engagements
"J&J has decided not to exercise its license option for HexaBody-CD38. Genmab will discontinue further clinical development of HexaBody-CD38 maintaining its previously stated focus on advancing late-stage assets Rina-S and acasunlimab. HexaBody-CD38 showed slightly higher ORR VGPR and CR rates compared to daratumumab though the differences were not substantial"
X Link @onco_park 2025-03-10T14:37Z 2361 followers, 4105 engagements